COMMUNIQUÉS West-GlobeNewswire

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
07/02/2024
ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24. Mild Alzheimer’s Patients Who Received Simufilam Non-Continuously [...]
Labcorp Elevates Employee Health Benefits with WeightWatchers for Business Full-Spectrum Weight Health Platform
07/02/2024
NEW YORK and BURLINGTON, N.C., Feb. 07, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW), (“WeightWatchers,” “WW,” or the “Company”) today announced that Labcorp (NYSE: LH), a global leader of innovative and [...]
LAPIX Therapeutics Strengthens Board of Directors with Appointments of Pharmaceutical Industry Veterans Henry A. McKinnell, Ph.D., Anthony Gibney, and Francisco Leon, MD, Ph.D.
07/02/2024
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases, [...]
Global Life Sciences Data Leader H1 Releases GenosAI™ Pro to Empower Clinical Ops Leaders with Conversational AI
07/02/2024
Debuting at SCOPE Summit 2024, the pro version of H1's proprietary GenAI tool expands access to deep insights within Trial Landscape solution to better facilitate clinical trial design and development NEW YORK, Feb. 07 [...]
U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize
07/02/2024
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department [...]
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
07/02/2024
HAMILTON, BERMUDA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy, when integrating Altamira’s [...]
Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine
07/02/2024
Increasing access to Imaging Mass Cytometry in pharmaceutical and clinical research settings SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose [...]
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07/02/2024
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. [...]
Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code
07/02/2024
DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc. (Nasdaq: TRIB) (the “Company”) today announced that its New York based reference laboratory, Immco Diagnostics, has applied for a Proprietary [...]
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
07/02/2024
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with [...]
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series
07/02/2024
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, [...]
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
07/02/2024
Biodexa Pharmaceuticals PLC Biodexa Announces Allowance of U.S. Patent Covering Tolimidone Biodexa plans to initiate a Phase 2 clinical program of tolimidone in Type 1 diabetes, following several preclinical studies [...]
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
07/02/2024
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today [...]
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
07/02/2024
Proven Industry Executive Brings More Than 25 Years of Leadership Experience FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage [...]
MatrixCare Earns Three 2024 Best in KLAS Awards
07/02/2024
MatrixCare has been named a market leader by KLAS Research for its Home Health EHR in three Categories: Home Health – Independent – Large, Home Health – Independent – Small, and Hospice – Independent BLOOMINGTON, Minn [...]
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
07/02/2024
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC [...]
Nextech Named 2024 Best in KLAS: Ambulatory Specialty EHR
07/02/2024
TAMPA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nextech, a leading provider of clinical and administrative healthcare technology solutions for specialty physician practices, today announced its EHR software is a top- [...]
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
07/02/2024
REDWOOD CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) [...]
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
07/02/2024
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with the Phase 3 [...]

Pages